Valuation: SANA AB

Market Cap 1.84B 190M 167M 153M 142M 271M 18.15B 274M 715M 8.91B 715M 699M 30.89B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.84B 190M 167M 153M 142M 271M 18.15B 274M 715M 8.91B 715M 699M 30.89B EV / Sales 2026 *
6.88x
EV / Sales 2027 * 4.74x
Free-Float
81.6%
Yield 2026 *
-
Yield 2027 * -
1 day-3.64%
1 week-1.01%
Current month-2.36%
1 month-0.31%
3 months-17.47%
6 months-39.62%
Current year-39.62%
1 week 12.68
Extreme 12.68
13.83
1 month 12.25
Extreme 12.25
13.83
Current year 12.25
Extreme 12.25
28.3
1 year 8.03
Extreme 8.03
28.3
3 years 1.74
Extreme 1.736
28.3
5 years 1.57
Extreme 1.572
28.3
10 years 1.57
Extreme 1.572
55
Manager TitleAgeSince
Chief Operating Officer 54 28/02/2025
Chief Tech/Sci/R&D Officer 68 31/12/2013
Chief Executive Officer 66 29/04/2022
Director TitleAgeSince
Chairman 71 29/04/2022
Director/Board Member 68 31/12/2014
Director/Board Member 46 18/01/2018
Date Insider Type Main position Quantity % Market Cap.
12-28Sell

Chief Executive Officer

5,000 0.0036%
12-28Sell

Chief Executive Officer

5,000 0.0036%
12-28Sell

Chief Executive Officer

5,000 0.0036%
Change 5-day change 1-year change 3-year change Capi.($)
-3.83%-1.01%+29.69%+80.28% 190M
-2.14%+3.65%+74.05%+131.89% 59.1B
-0.93%+4.05%+73.64%+90.53% 55.19B
+5.11%+0.01%-14.34%-10.86% 24.67B
-1.87%+6.83%+15.41%+453.09% 24.19B
+0.64%+14.41%+44.27%-3.20% 19.69B
-2.19%+6.34%+39.72%-29.60% 17.56B
+3.58%+25.11%+196.41%+363.46% 16.22B
+4.91%+25.24%+44.61% - 14.84B
-0.87%+2.09%+25.49%+186.68% 14.04B
Average -0.37%+7.79%+52.89%+140.25% 24.57B
Weighted average by Cap. -0.66%+6.42%+57.96%+136.16%

Financials

2026 *2027 *
Net sales 267M 27.65M 24.22M 22.31M 20.7M 39.32M 2.64B 39.85M 104M 1.29B 104M 102M 4.49B 388M 40.16M 35.17M 32.4M 30.07M 57.1M 3.83B 57.88M 151M 1.88B 151M 148M 6.52B
Net income - -
Net Debt - -
Logo SANA AB
Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.
Employees
43
Date Price Change Volume
06/07/26 SEK 12.80 -3.83% 311,917
03/07/26 SEK 13.31 +4.80% 801,874
02/07/26 SEK 12.70 -1.70% 262,464
01/07/26 SEK 12.92 -1.45% 149,328
30/06/26 SEK 13.11 +1.39% 286,033

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SANION Stock